Antihypertensive treatment and stroke prevention: Are angiotensin receptor blockers superior to other antihypertensive agents?

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 3, 2009, Pages 197-204

  Armario, Pedro ^a   Sierra, Alejandro ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Hypertension; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EMBUSARTAN; EPROSARTAN; LOSARTAN; NITRENDIPINE; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ADD ON THERAPY; ARTERIOSCLEROSIS; BLOOD PRESSURE REGULATION; BRAIN INFARCTION; BRAIN INJURY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FORMULATION; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INCIDENCE; MORBIDITY; MORTALITY; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE; WHITE MATTER;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; PROGNOSIS; SECONDARY PREVENTION; STROKE;

EID: 67449115713     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944709104164     Document Type: Review

References (49)

1. Amarenco, P. and Steg, P.G. (2008) Stroke is a coronary heart disease equivalent: implications for future clinical trials in secondary stroke prevention. Eur Heart J 29: 1606-1607.
2. Angeli, F., Verdecchia, P., Reboldi, G.P., Gattobigio, R., Bentivoglio, M., Staessen, J.A. et al. (2004) Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 17: 817-822.
3. Arenillas, J.F., Candell-Riera, J., Romero-Farina, G., Molina, C.A., Chacón, P., Aguadé-Bruix, S. et al. (2005) Silent myocardial ischemia in patients with symptomatic intracranial atherosclerosis. Associated factors. Stroke 36: 1201-1206.
4. ArenTouzé, E., Varenne, O., Chatellier, G., Peyrard, S., Rothwell, P.M. and Mas, J.L. (2005) Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke. A systematic review and meta-analysis. Stroke 36: 2748-2755.
5. Arosio, E., de Marchi, S., Prior, M., Rigoni, A. and Lechi, A. (2005) Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress. J Hypertens 23: 1923-1927.
6. Balt, J., Mathy, M.J., Pfaffendorf, M. and van Zwieten, P.A. (2001) Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. J Hypertens 19: 2241-2250.
7. Bhatt, D.L., Steg, P.G., Ohman, E.M., Hirsch, A.T., Ikeda, Y., Mas, J.L. et al. (2006) International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis. J Am Med Assoc 295: 180-189.
8. Brainin, M., Teuschl, Y. and Kalra, L. (2007) Acute treatment and long-term management of stroke in developing countries. Lancet Neurol 6: 553-561.
9. Das, R.R., Seshadri, S., Beiser, A.S., Kally-Hayes, M., Au, R., Himali, J.J. et al. (2008) Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke 39: 2929-2935.
10. Dahlöf, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., de Faire, U. et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003.
11. Dahlöf, B. (2008) Preventing stroke in hypertensive patients at risk. J Am Soc Hypertens 2: S38-S45.
12. de la Sierra, A. and Sierra, C. (2006) Cerebral white matter lesions. Risk of stroke and cerebrovascular protection with angiotensin receptor blockers. Curr Drug Ther 1: 9-16.
13. de Leeuw, F.E., de Groot, J.C., Oudkerk, M., Witteman, J.C., Hofman, A., van Gijn, E.J. et al. (1999) A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol 46: 827-833.
14. Devereux, R.B., Wachtell, K., Gerdts, E., Boman, K., Nieminen, M.S., Papademetriou, V. et al. (2004) Prognostic significance of left ventricular mass change during the treatment of hypertension. J Am Med Assoc 292: 2350-2356.
15. Diener, H.C., Sacco, R.L., Yusuf, S., Cotton, D., Ôunpuu, S., Lawton, W.A. et al. (2008) Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effecticvely Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 7: 875-884.
16. European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008, Cerbrovasc Dis 25: 457-507.
17. Fournier, A., Messerli, F.H., Achard, J.M. and Fernandez, L. (2004) Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 43: 1343-1347.
18. Goldstein, L.B., Adams, R., Alberts, M.J., Appel, L.J., Brass, L.M., Bushnell, C.D. et al. (2006) Primary prevention of ischemic stroke. A Guideline from the American Heart Assocation / American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcome Research Interdisciplinary Working Group. Stroke 37: 1583-1633.
19. Guimaraes, S., Pinheiro, H., Tavares, P., Loio, A. and Moura, D. (2001) Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors. Naunyn-Schmiedebergs Arch Pharmacol 363: 509-514.
20. Hankey, G.J. and Eikelboom, J.W. (2008) What do the results of the PRoFESS trial teach us? Lancet Neurol 7: 860-862.
21. Lewington, S., Clarke, R., Qzibash, N., Peto, R., Collins, R. and for the Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individuals data for one million adults in 61 prospective studies. Lancet 360: 1903-1913.
22. Li, J., Culman, J., Hortnagl, H., Zhao, Y., Gerova, N., Timm, M. et al. (2005 c) Angiotensin AT 2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 19: 617-619.
23. Li, C., Engstrom, G., Hedblad, B., Berglund, G. and Janzon, L. (2005 a) Blood pressure control and risk of stroke: a population-based prospective cohort study. Stroke 36: 725-730.
24. Li, C., Engstrom, G., Hedblad, B., Berglund, G. and Janzon, L. (2005 b) Risk factors for stroke in subjects with normal blood pressure: a prospective cohort study. Stroke 36: 234-238.
25. Lindholm, L.H., Carlberg, B. and Samuelsson, O. (2005) Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545-1553.
26. Lithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B. et al. (2003) The Study On Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomized double-blind intervention trial. J Hypertens 21: 875-886.
27. Lopez, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T. and Murray, C.J. (2006) Global and regional burden of disease and risk factors, 2001: a systematic analysis of population health data. Lancet 367: 1747-1757.
28. Mancia, G., de Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G. et al. (2007) 2007 guidelines for the management of arterial hypertension. J Hypertens 25: 1105-1187.
29. Mochizuki, S., Dahlöf, B., Shimizu, M., Ikewaki, K., Yoshikawa, M., Taniguchi, I. et al. (2007) Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369: 1431-1439.
30. Nakashima, H., Kumagai, K., Urata, H., Gondo, N., Ideishi, M. and Arakawa, K. (2000) Angiotensin II antagonist prevents electrical remodelling in atrial fibrillation. Circulation 101: 2612-2617.
31. Okin, P.M., Devereux, R.B., Jerns, S., Kjeldsen, S.E., Julius, S., Nieminen, M.S. et al. (2004) Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. J Am Med Assoc 292: 2343-2349.
32. Ontarget Investingators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.
33. Pantoni, L. and García, J.H. (1995) The significance of cerebral white matter abnormalities 100 years after Binswanger's report. Stroke 26: 1293-1301.
34. PROGRESS Collaborative group (2001) Randomised trial of perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033-1041.
35. Reboldi, G., Angeli, F., Cavallini, C., Gentile, G.; Mancia, G. and Verdecchia, P. (2008) Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 26: 1282-1289.
36. Redón, J., Cea-Calvo, L., Lozano, J.V., MartíCanales, J.C., Llisterri, J.L., Aznar, J. et al. (2007) Differences in blood pressure control and stroke mortality across Spain. The Prevención de Riesgo de Ictus (PREV-ICTUS) Study. Hypertension 49: 799-805.
37. Sacco, R.L., Diener, H.C., Yusuf, S., Cotton, D., Ôunpuu, S., Lawton, W.A. et al. (2008) Aspirin and extended-release dypiridamole versus clopidogrel for recurrent stroke. N Engl J Med 359: 1238-1251.
38. Schrader, J., Lüders, S., Kulschewski, A., Hammersen, F., Plate, K., Berger, J. et al. (2005) Morbidiy and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218-1224.
39. Sierra, C., de la Sierra, A., Mercader, J., Gómez-Angelats, E., Urbano-Marquez, A. and Coca, A. (2002) Silent cerebral white matter lesions in middle-aged essentials hypertensive patients. J Hypertens 20: 519-520.
40. Sierra, C. and de la Sierra, A. (2005) Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin receptor blockers. Curr Opin Nephrol Hypertens 14: 435-441.
41. Staessen, J.A., Fagard, R., Thijs, L., Celis, H., Arabidze, G.G., Birkenhäger, W.H. et al. (1997) Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350: 757-764.
42. Staessen, J.A., Gasowski, J., Wang, J.G., Thijs, L., Den Hond, E., Boissel, J.P. et al. (2000) Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355: 865-872.
43. Staessen, J.A., Wang, J.G. and Thijs, L. (2003) Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 1, 2003. J Hypertens 21: 1055-1076.
44. Turnbull, F., Blood Pressure Lowering Treatment Trialists' Collaboration (2003) Effect of different blood-pressure lowering regimens on major cardiovascular events: results of prospective-designed overviews of randomised trials, Lancet 362: 1527-1535.
45. Vermeer, S.E., den Heijer, T., Koudstaal, P.J., Oudkerk, M., Hofman, A. and Breteler, M.M.B. (2003) Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 34: 392-396.
46. Wachtell, K., Hornestan, B., Lehto, M., Slotwiner, D.J., Gerdst, E., Olsen, M.H. et al. (2005) Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation. The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol 45: 705-711.
47. Wardlaw, J.M. (2008) What is a lacune? Stroke 39: 2921-2922
48. Wolf-Maier, K., Cooper, R.S., Banegas, J.R., Giampoli, S., Hense, H.W., Joffres, M. et al. (2003) Hypertension prevalence and blood pressure levels in six European countries, Canada, and the United States. J Am Med Assoc 289: 2363-2369.
49. Yusuf, S., Diener, H.C., Sacco, R.L., Cotton, D., Ôunpuu, S., Lawton, W.A. et al. (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359: 1225-1237.